Details for Patent: 10,189,833

Which drugs does patent 10,189,833 protect, and when does it expire?

Patent 10,189,833 protects TURALIO and is included in one NDA.

This patent has fifty-one patent family members in twenty-eight countries.

Summary for Patent: 10,189,833

Title:	Solid forms of a compound modulating kinases
Abstract:	Solid forms of the compound, [5-(5-chloro-1H-pyrrolo[2,3-b]pyridin-3-ylmethyl)-pyridin-2-yl]-(6-triflu- oromethyl-pyridin-3-ylmethyl)-amine HCl salt (Compound I) and its free base, active on the receptor protein kinases c-Kit and/or c-Fms and/or Flt3, were prepared and characterized: ##STR00001## Also provided are methods of using the solid forms.
Inventor(s):	Ibrahim; Prabha N. (Mountain View, CA), Visor; Gary Conard (Castro Valley, CA)
Assignee:	Plexxikon Inc. (Berkeley, CA)
Application Number:	15/725,197
Patent Claim Types: see list of patent claims	Use; Composition; Device;

Drugs Protected by US Patent 10,189,833

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-002	Oct 14, 2022		RX	Yes	No						TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY
Daiichi Sankyo Inc	TURALIO	pexidartinib hydrochloride	CAPSULE;ORAL	211810-001	Aug 2, 2019		DISCN	Yes	No						TREATMENT OF ADULT PATIENTS WITH SYMPTOMATIC TENOSYNOVIAL GIANT CELL TUMOR (TGCT) ASSOCIATED WITH SEVERE MORBIDITY OR FUNCTIONAL LIMITATIONS AND NOT AMENABLE TO IMPROVEMENT WITH SURGERY

International Family Members for US Patent 10,189,833

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2016258027
Brazil	112017023490
Brazil	112017023540
Canada	2984899